Convalescent plasma is an ineffective treatment for patients with COVID-19

What is this research about?

Convalescent plasma (plasma collected from individuals who have recovered from an infection) has historically been used to treat various diseases, including SARS-CoV-1, MERS-CoV, and influenza. At the onset of the COVID-19 pandemic, convalescent plasma from individuals who had recovered from COVID-19 stood as a potential antibody-based treatment for patients. However, there was insufficient evidence at the time on the safety and risks of COVID-19 convalescent plasma (CCP). In May 2020, the CONCOR-1 trial was developed to explore CCP as a potential treatment for patients with COVID-19. This Canadian-led international clinical trial compared convalescent plasma and standard-of-care for hospitalized adults with acute COVID‑19 respiratory illness requiring supplemental oxygen.

Published on